Back to Browse Journals » Journal of Pain Research » Volume 3

An open-label, non-randomized comparison of venlafaxine and gabapentin as monotherapy or adjuvant therapy in the management of neuropathic pain in patients with peripheral neuropathy

Authors William Eardley, Cory Toth

Published Date April 2010 Volume 2010:3 Pages 33—49

DOI http://dx.doi.org/10.2147/JPR.S8675

Published 1 April 2010

William Eardley, Cory Toth

Department of Clinical Neurosciences and the University of Calgary, Calgary, AB, Canada

Abstract: Although many therapies are used in the management of neuropathic pain (NeP) due to polyneuropathy (PN), few comparison studies exist. We performed a prospective, non-randomized, unblended, efficacy comparison of the serotonin-norepinephrine reuptake inhibitor venlafaxine, as either monotherapy or adjuvant therapy, with a first-line medication for NeP, gabapentin, in patients with PN-related NeP. VAS pain scores were assessed after 3 and 6 months in intervention groups and in a cohort of patients receiving no pharmacotherapy. In a total of 223 patients, we analyzed pain quantity and quality (visual analogue scale [VAS] score, Brief Pain Inventory [BPI]), quality of life and health status measures [EuroQol 5 Domains, EQ-5D], Medical Outcomes Sleep Study Scale [MOSSS], Hospital Anxiety and Depression Scale [HADS] and Short Form 36 Health Survey [SF-36]) after 6 months of therapy. Significant improvements in VAS pain scores occurred for all treatment groups after 6 months. Improvements in aspects of daily life and anxiety were identified in all treatment groups. Our data suggest that monotherapy or adjuvant therapy with venlafaxine is comparable to gabapentin for NeP management. We advocate for head-to-head, randomized, double-blinded studies of current NeP therapies.

Keywords: peripheral neuropathy, neuropathic pain, pharmacotherapy, venlafaxine, gabapentin

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

The importance of catastrophizing for successful pharmacological treatment of peripheral neuropathic pain

Toth C, Brady S, Hatfield M

Journal of Pain Research 2014, 7:327-338

Published Date: 24 June 2014

Readers of this article also read:

Problems and barriers of pain management in the emergency department: Are we ever going to get better?

Sergey M Motov, Abu NGA Khan

Journal of Pain Research 2009, 2:5-11

Published Date: 9 December 2008

Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy

Daniel Z Lieberman, Suena H Massey

Core Evidence 2009, 4:67-82

Published Date: 25 June 2009

Acute pain management in children

Susan T Verghese, Raafat S Hannallah

Journal of Pain Research 2010, 3:105-123

Published Date: 15 July 2010

New and emerging therapeutic agents for the treatment of fibromyalgia: an update

Jill M Recla

Journal of Pain Research 2010, 3:89-103

Published Date: 22 July 2010

Anesthesiologists’ perception of patients’ anxiety under regional anesthesia

Hatem A Jlala, Nigel M Bedforth, Jonathan G Hardman

Local and Regional Anesthesia 2010, 3:65-71

Published Date: 12 August 2010

Duloxetine in the treatment of chronic pain due to fibromyalgia and diabetic neuropathy

Alan Wright, Kyle E Luedtke, Chad VanDenBerg

Journal of Pain Research 2011, 4:1-10

Published Date: 16 December 2010

Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder

Xianchen Liu, Yi Chen, Douglas E Faries, et al

ClinicoEconomics and Outcomes Research 2011, 3:63-72

Published Date: 15 March 2011